KYTX
Kyverna Therapeutics, Inc. Common Stock
NASDAQ: KYTX · HEALTHCARE · BIOTECHNOLOGY
$10.23
-6.04% today
Updated 2026-06-05
Market cap
$490.62M
P/E ratio
—
P/S ratio
3,513.34x
EPS (TTM)
$-3.27
Dividend yield
—
52W range
$3 – $14
Volume
1.0M
Kyverna Therapeutics, Inc. Common Stock (KYTX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-79.97%
ROA
-39.60%
Debt/equity
0.17x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2021 | $5.66M | $-26.35M | 100.00% | -465.81% | -465.88% |
| 2022 | $7.03M | $-28.89M | 100.00% | -418.28% | -411.29% |
| 2023 | $0.00 | $-60.37M | — | — | — |
| 2024 | $0.00 | $-127.48M | — | — | — |
| 2025 | $0.00 | $-161.31M | — | — | — |
Frequently asked questions
How much free cash flow does KYTX generate?
KYTX produced $-153.72M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is KYTX's balance sheet healthy?
KYTX holds $124.09M in cash and equivalents against $24.74M in long-term debt, on $232.28M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.